ALECTOS THERAPEUTICS INC.: federal grants and contributions: 18 agreements; $3.1M value; 1 departments; 5 programs.
Assay record ASY-CA-1LM1IS110M · Cite as: Assay Systems, “ALECTOS THERAPEUTICS INC.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/alectos-therapeutics-inc/
Novel small molecule modulators as potential therapeutics for a rare brain disease, Niemann-Pick Type C, will be evaluated in preclinical studies.
The project will characterize and validate novel small molecule glucocerebrosidase 2 inhibitors as disease-modifying therapeutics for Parkinson’s disease.
Novel targeted small molecule modulators will be designed, tested and characterized as disease-modifying therapeutics for Niemann-Pick Type C disease.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
In this project, the Graduate will be involved in recombinant protein synthesis, biochemical assay development and characterization of novel small molecule enzyme inhibitors that have potential as treatments of acute ischemic stroke.
This project will involve assay development and characterization of novel small-molecule glucocerebrosidase inhibitor/modulator therapeutics for Parkinson’s disease.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.